Regulatory Considerations for Global Sleep Supplements

Introduction

The global demand for sleep supplements is growing rapidly as consumers seek natural, non-pharmaceutical solutions to improve rest and recovery. Yet for brands, formulating and marketing these products internationally presents a unique challenge: regulations on sleep aids vary widely by country. What qualifies as a dietary supplement in one market may be regulated as a drug in another.

This article outlines the key regulatory considerations for global sleep supplements, covering label claims, ingredient restrictions, filing and notification requirements, and practical compliance strategies. By understanding these regional frameworks—across the U.S., EU, Canada, Australia, and Asia—companies can navigate approvals confidently and protect both brand credibility and consumer trust.

1. Why compliance matters for sleep supplements

Sleep complaints are widespread and growing, which attracts both consumers and regulators. Recent systematic reviews show high global prevalence of insomnia and sleep disturbances, particularly in older adults—underscoring why authorities closely keep watch on sleep-related claims and ingredients.

This means doing two things well:

1. Design your formulation around ingredients whose status is clear (e.g., vitamins/minerals, certain botanicals).
2. Engineer your label to the claim types your markets permit—and hold the evidence those claim demands.

2. Label claims: what you can (and cannot say)

2.1 United States (FDA +FTC)

1. Structure/function claims such as “supports healthy sleep” or “helps you fall asleep faster” (without naming a disease) are permitted for dietary supplements if you:
   • Notify FDA within 30 days of first marketing the product.
   • Include the exact disclaimer: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
   • Hold adequate substantiation (competent and reliable scientific evidence). Disease claims (e.g., “treats insomnia”) are prohibited.
2. FDA requires dietary supplement cGMPs (21 CFR Part 111)  covering quality systems, specifications, master/batch records, testing, and complaint handling.

2.2 Practical U.S. label checklist:

1. Choose structure/function (not disease) language.
2. Add the FDA disclaimer, place it adjacent to the claim.
3. File the 30-day notification to FDA.
4. Align substantiation files to the specific wording used on label/digital ads.

2.3 European Union (EU) and Great Britain (GB)

1. The EU’s Food Supplements Directive 2002/46/EC harmonizes the category and lists vitamins/minerals permitted as ingredients; non-harmonized elements (e.g., maximum levels, many botanicals) remain member-state matters.
2. Health claims must be authorized under the Nutrition & Health Claims Regulation. A pivotal example for sleep: melatonin has an authorized claim—”contributes to the reduction of time taken to fall asleep”—with conditions of use; EFSA’s scientific opinion substantiated this at 1 mg shortly before bedtime (and a separate jet-lag claim). GB retains its own NHC Register post-Brexit, mirroring the EU with domestic maintenance.
3. In the EU, most botanical health claims remain “on hold” pending further evaluation—marketing often uses softer, non-specific wording, but you must still ensure the claim is truthful, not misleading, and consistent with the general claims framework. (Recent EU case-law keeps this area dynamic—always check the current status before launch.)

2.4 Practical EU/GB label checklist

1. If using melatonin, match the exact authorized claim wording and conditions of use (dose/timing). Keep records of your formulation meeting the condition.
2. If using magnesium or other nutrients, use authorized function claims only.
3. For botanicals, assess if your wording risks implying a health claim that is not authorized; consider consumer-friendly but non-specific benefits and avoid disease terms.
4. For GB, verify against the GB NHC Register and CAP Code advertising rules.

2.5 Canada

Sleep supplements are Natural Health Products (NHPs) and require a product license (NPN) before sale. Health Canada publishes monographs with allowed uses, doses, and risk statements that, if met, can fast-track applications. Licensed products are searchable in the LNHPD.

2.6 Practical Canada label checklist

1. Build claims strictly from the relevant monograph (or provide evidence otherwise).
2. Display NPN on labels once issued; include risk statements specified by the monograph.

2.7 Australia

Most sleep supplements are Listed Medicines (AUST L) on the ARTG. Your claims must be chosen from the Permissible Indications Determination (e.g., “relieve sleeplessness” including traditional-use indications) and supported by evidence on file. Labels/ads must align to the selected indications. Recent 2025 updates refreshed the permitted indications list—check the latest instrument.

2.8 Practical Australia label checklist

1. Pick indications only from the Permissible Indications list.
2. Keep an evidence file (scientific or traditional) ready for TGA review.
3. Ensure label/advertising copy matches selected indications and avoids restricted representations.

2.9 Asia

1. Sleep aids in India are “nutraceuticals”. Only generic well-being claims are allowed. Melatonin is not permitted as a supplement—it’s a prescription drug. Botanicals like ashwagandha or valerian are allowed if listed.
2. ASEAN (Singapore, Malaysia, Indonesia, Thailand) countries have harmonizing rules but each country has its own enforcement. Claims must be function-only. No disease terms like insomnia.
   • Singapore: Melatonin is prescription-only.
   • Malaysia & Indonesia: Function claims okay; melatonin not allowed in supplements. Traditional-use wording is acceptable.
3. In Japan, foods can carry sleep-support claims only through the FFC route, with pre-market notification and human evidence. Melatonin + drug, not allowed in food supplements.
4. Sleep supplements in Korea must be Health Functional Foods with approved functional ingredients. Again, melatonin = drug, not food.
5. In China, “health foods” may claim “improves sleep” if registered and tested per SAMR’s 2023 catalogue. Melatonin is permitted in health foods, subject to strict controls.
6. Like Korea, melatonin in Taiwan is also considered a drug so supplements must use other actives like botanicals.
7. Any product claiming to “treat insomnia” is a medicine in Hong Kong. Supplements can only use soft, general claims. Melatonin is handled as a pharmaceutical.

3. Ingredient restrictions that trip brands up

3.1 Ingredient Restrictions in EU & GB

In the EU, melatonin sits in a regulatory grey zone. EFSA has authorized a health claim but in practice, many Member States classify melatonin above certain thresholds, and in some cases at any dose, as a medicinal product. This means a product containing melatonin could be pulled into the medicines framework instead of being sold as a food supplement. Botanical claims are also restricted; under the Nutrition and Health Claims Regulation, most botanical health claims remain “on hold”, which prevents companies from using explicit or therapeutic wording. Botanicals like valerian or chamomile may still be included in products, but claims must remain non-specific and must not imply treatment of insomnia or other sleep disorders.

Great Britain follows a similar approach to the EU but with its own post-Brexit registers. The MHRA has licensed multiple melatonin products as medicines, so melatonin is generally treated as a pharmaceutical ingredient rather than a supplement. As in the EU, botanical health claims are largely restricted. Marketers can include botanicals such as valerian, passionflower, or chamomile in formulations, but again without explicit authorization, disease, or therapeutic claims.

3.2 Ingredient Restrictions in Canada

Canada provides a clearer framework for sleep-related supplements through its Natural Health Products (NHP) regime. Melatonin has a published Health Canada monograph that specifies permitted claims, dosing ranges, and mandatory cautionary statements. Products that comply can obtain a Natural Product Number (NPN) license quickly. Botanical ingredients are also managed under Health Canada’s Compendium of Monographs.

3.3 Ingredient Restrictions in Australia

In Australia, melatonin is generally regulated as prescription medicine. It cannot be freely sold in dietary supplements and must be listed as a therapeutic good on the Australia Register of Therapeutic Goods (ARTG). Botanicals, however, may be used more flexibly under the “listed medicines” pathway. Claims based on traditional use are acceptable with claim wording taken from the official Permissible Indications Determination and supported evidence of traditional use.

3.4 Ingredient Restrictions in Asia

Melatonin across Asian markets is treated inconsistently. It is permitted as a health food ingredient in China when registered for the “improves sleep” function, but it is considered a drug in most other Asian countries (MHLW, 2011; MFDS, 2021; TFDA, 2019; Thai FDA, 2020; Philippines FDA, 2020). Indonesia allows melatonin only as a special-use health supplement with pharmacy-only distribution under BPOM’s rules. For botanicals, countries differ on positive and negative lists: Korea permits only MFDS-recognized functions ingredients, China restricts use to catalogue-listed raw materials unless formally registered, and Southeast Asian countries allow many traditional botanicals but prohibit claims that imply pharmacological effects.

4. Filing/notification requirements by market

4.1 United States

No premarket approval for most supplements, but:

1. NDI Notification to FDA 75 days before marketing if your dietary ingredient is “new” (not marketed in the U.S. before Oct 15, 1994, or without an applicable history of use).
2. Structure/function claim 30-day notification after first use.
3. cGMP compliance (21 CFR 111) with full quality documentation.

4.2 EU and Member States

No EU-wide premarket approval for standard food supplements, but Member States may require product notifications to their competent authority (often a label model upload). Many do. The Commission confirms states may request notification for monitoring.

4.3 Great Britain

Claims must align to GB NHC Register; ingredients like melatonin are generally medicines when presented for therapeutic purposes. Where a borderline decision applies, MHRA guidance shows how classification is made.

4.4 Canada

Pre-market licensing: obtain an NPN via dossier or monograph route; then list in LNHPD. Site licensing and GMPs also apply.

4.5 Australia

ARTG listing (AUST L) through TGA Business Services; then choose permitted indications, retain substantiation; comply with labeling and advertising rules. Recent 2025 Determination update applies.

4.6 Asia

1. Singapore does not require pre-market approval for supplements, but companies are fully responsible for compliance.
2. Malaysia requires product registration with NPRA before sale, Indonesia requires BPOM registration, and melatonin supplements face additional pharmacy-only restrictions.
3. Thailand requires supplements to be registered and health claims assessed under MOPH regulations.
4. The Philippines requires a Certificate of Product Registration (CPR) from the FDA plus the No Approved Therapeutic Claims disclaimer on all labels.
5. In India, nutraceuticals require licensing through FSSAI’s FoSCoS platform, while melatonin products must go through CDSCO drug route.
6. China mandates filing or registration depending on whether the ingredients/functions are in the approved catalogue.
7. Japan requires pre-notification for FFC claims or approval for FOSHU, while melatonin products must use the drug pathway.
8. Korea requires registration of Health Functions Foods using MFDS-recognized ingredients.
9. Taiwan requires a Health Food permit for any functional claim and Hong Kong requires drug registration for any supplement with melatonin or therapeutic claims.

5. How to write compliant sleep claims

1. For the U.S.: “supports healthy sleep quality and nighttime relaxation” (structure/function). Include the FDA disclaimer and file the 30-day notice.
2. EU/GB (melatonin): “melatonin contributes to the reduction of time taken to fall asleep. The beneficial effect is obtained by consuming 1 mg shortly before bedtime.” Use only with qualifying composition/dose.
3. Australia: Select an approved indication where permitted; ensure exact phrasing matches the Determination and your evidence basis.
4. Canada: Wording should mirror the monograph (e.g., “helps increase total sleep time in people with sleep restriction/altered sleep schedule,” as applicable to the melatonin monograph).
5. Asian countries: Explicit references to insomnia, anxiety, or treatment are not permitted. In Singapore and Malaysia, only general function claims are acceptable, while the Philippines enforces mandatory disclaimer on all supplement labels. In China, claims must strictly follow the official catalogue wording “helps improve sleep,” with functional testing evidence on file. Japan allows brands to make sleep-quality claims under the FFC system but requires human clinical data and pre-notification to the CAA, while any mention of melatonin automatically triggers drug regulation. Korea requires companies to adopt only MFDS-approved function claims, and Taiwan allows sleep-related wording only for products with a Health Food permit. Across Hong Kong, any sleep-related claim that implies treatment moves the product into the medicine category.

5.1 Copywriting guidelines for all markets

1. Don’t use disease words (e.g., insomnia, sleep apnea) unless you’re on a medicine route.
2. Avoid comparative/quantified performance (e.g., “falls asleep 50% faster”) unless your evidence is robust and market-specific rules allow it.

6. Labels that pass regulator reviews: mandatory elements by region

6.1 United States

• Statements of identity (“Dietary supplement”)
• Net quantity
• Supplement facts, ingredients, allergen
• Manufacturer/distributor info
• Directions, warning(s), structure/function disclaimer (if applicable)
• cGMP batch records must trace every label version

6.2 EU & GB

• Food supplements identity
• Recommended daily portion, warning not to exceed
• Warnings such as, “not a substitute for a varied diet,” “keep out of reach of young children.”
• Nutrient amounts, allergens, country-specific particulars; authorized health claims only with conditions of use.

6.3 Canada

• NPN
• Dosage form/route, recommended use(s) per monograph, dose
• Caution statements
• Lot/expiry
• Bilingual labeling.

6.4 Australia

• ARTG number (AUST L)
• Dosage/directions, permitted indications as selected
• Mandatory warning statements (if any)
• Label presentation aligned with TGA guidance

6.5 Asia

• Sleep supplements in China require the official “Blue Hat” logo and health food registration or filing number. Exact authorized wording, clear dosage, and warnings are also mandatory.
• In Japan, Foods with Function Claims must state functional wording, summary of scientific evidence, recommended daily intake, nutrient content, and disclaimer.
• Korean Health Functional Foods require the MFDS-approved function statement, active ingredient per serving, daily intake, and Health Functional Food mark with approval number.
• In Taiwan, sleep supplements may carry a claim only if they have a TFDA-issue Health Food permit shown on the label along with approved wording, dosage, and disclaimer.
• In Hong Kong, any product with therapeutic claims must display a registration number and approved indications.
• Across Southeast Asia, regulatory registration numbers are required along with ingredients, dosage, and warnings. In the Philippines, the “No Approved Therapeutic Claims” statement is compulsory.

7. Frequently overlooked risks

1. Implied disease claims via graphics or testimonials—still a disease claim in the U.S./EU/GB.
2. Botanical name-drops that imply medicinal action (especially in the EU where claims are on hold).
3. Melatonin is sold as a “supplement” into markets where it’s treated as a medicine (GB, many EU states, several APAC countries)—ensure classification checks per country and route accordingly. (GB medicines listings illustrate classification.)
4. Missing filings

8. Piacio®’s compliance tips

1. Lead with permitted specificity. In EU/GB, if you use melatonin, the authorized “reduced time to fall asleep” claim (with 1 mg timing) is clear when paired with consumer-friendly benefits (e.g., “drift off sooner”).
2. Translate science into allowed language. If your evidence shows improved sleep quality, in the U.S. that’s a viable structure/function phrase; in the EU, switch to fatigue-focused nutrient claims if you’re relying on magnesium.
3. Flexible labels. Keep claim and warning panels modular so you can swap per market without re-laying the entire design.
4. Document everything. Most enforcement pain comes from missing evidence files or misaligned ad copy—not from the label itself.

The highest-converting sleep brands are the ones that never have to pull a label or pause ads for compliance. If you bake in these frameworks from day one—and adjust your formulation/claims per market—you protect growth and the trust you’re building with consumers. Piacio®’s role is to turn the complexity of sleep supplement regulations into a predictable launch path.

References

1. U.S. Food and Drug Administration (FDA). (2023). Structure/Function Claims Guidance; 21 CFR 101.93.
   https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims
2. U.S. Food and Drug Administration (FDA). (2023). Dietary Supplement Current Good Manufacturing Practice (cGMP) Regulations; 21 CFR Part 111. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111
3. U.S. Food and Drug Administration (FDA). (2023). New Dietary Ingredient Notification; 21 CFR 190.6. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-190/subpart-B/section-190.6
4. European Commission. (2002). Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements. https://eur-lex.europa.eu/eli/dir/2002/46/oj/eng
5. European Commission. (n.d.). EU Register of Health Claims. https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/eu-register-health-claims_en
6. European Food Safety Authority (EFSA). (2011). Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency. EFSA Journal, 9(6), 2241. https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2011.2241
7. Department of Health and Social Care (UK). (2021). Great Britain Nutrition and Health Claims (NHC) Register. https://www.gov.uk/government/publications/great-britain-nutrition-and-health-claims-nhc-register
8. Medicines and Healthcare Products Regulatory Agency (MHRA). (2023). Borderline products: How to tell if your product is a medicine. https://www.gov.uk/guidance/borderline-products-how-to-tell-if-your-product-is-a-medicine
9. Health Canada. (2018). Melatonin (Oral) Monograph. https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_melatonin–oral_english.pdf
10. Health Canada. (2019). Compendium of Monographs. https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/product-licensing/compendium-monographs.html
11. Health Canada. (n.d.). Licensed Natural Health Products Database (LNHPD). https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/product-licensing/licensed-natural-health-products-database.html
12. Therapeutic Goods Administration (TGA). (2023a). Listed Medicines Overview. https://www.tga.gov.au/products/medicines/non-prescription-medicines/listed-medicines
13. Therapeutic Goods Administration (TGA). (2025). Therapeutic Goods (Permissible Indications) Determination. https://www.tga.gov.au/resources/legislation/therapeutic-goods-permissible-indications-determination
14. State Administration for Market Regulation (SAMR). (2023). Catalogue of Permitted Health Functions for Health Foods (includes “helps improve sleep”).
15. Consumer Affairs Agency (CAA) & Ministry of Health, Labour and Welfare (MHLW). Foods with Function Claims (FFC) and Foods for Specified Health Uses (FOSHU) systems.
16. Ministry of Food and Drug Safety (MFDS). Health Functional Foods Act and Recognized Functional Ingredients Catalogue.
17. Taiwan Food and Drug Administration (TFDA). Health Food Permit System.
18. Department of Health (DH). Pharmacy and Poisons Ordinance — Therapeutic Product Registration.
19. Health Sciences Authority (HSA). Guidelines for Health Supplements.
20. National Pharmaceutical Regulatory Agency (NPRA). Health Supplements Registration Guidance.
21. IBPOM. (2020). Decision on Melatonin as a Special-Use Health Supplement (HK.02.02.1.2.12.20.1417).
22. Thai FDA / Ministry of Public Health. (2023). MOPH Notification No. 447 — Health Claim Requirements for Foods.
23. Food and Drug Administration (FDA). (2020). Guidelines on Food-Dietary Supplements and “No Approved Therapeutic Claims” Statement.
24. World Health Organization. (2011). Quality Control Methods for Herbal Materials. WHO Press.
25. World Health Organization. (2018). Aflatoxins — Fact Sheet. WHO.
26. Fernandez-San-Martin, M. I., et al. (2010). Effectiveness of Valerian on Insomnia: A Meta-Analysis of Randomized Placebo-Controlled Trials. Sleep Medicine, 11(6), 505–511.
27. Zhao, J., Li, Y., Wang, T., & Zheng, Y. (2019). Melatonin Content in Pistachio (Pistacia vera L.) and Its Potential for Improving Sleep. Journal of Agricultural and Food Chemistry, 67(30), 8223–8230.
28. Ichim, M. C., & de Boer, H. (2020). Authenticity and Authentication of Herbal Medicinal Products. Frontiers in Pharmacology, 11, 572543.